Search
CNS-5161
go.drugbank.com/drugs/DB05824ExperimentalCNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
Barnidipine
go.drugbank.com/drugs/DB09227InvestigationalUsed in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of the smooth muscle cells in the vascular wall [L1131] and selectivity against cardiovascular L-type … Barnidipine has a gradual onset of action and is shown to be well tolerated in patients. It does not produce reflex tachycardia [A7842].
Delavirdine
go.drugbank.com/drugs/DB00705ApprovedInvestigationalWithdrawnA potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Synonyms: (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide), 2-(4-(5-methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamineEvans blue
go.drugbank.com/drugs/DB09361InvestigationalCategories: Compounds used in a research, industrial, or household settingParaoxon
go.drugbank.com/drugs/DB13495ExperimentalCategories: Compounds used in a research, industrial, or household settingTioguanine
go.drugbank.com/drugs/DB00352ApprovedInvestigationalAn antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Lecithin
go.drugbank.com/drugs/DB15834InvestigationalA complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.
Mixtures: ONE A DAY TABLETCategories: Compounds used in a research, industrial, or household settingUbiquinone Q2
go.drugbank.com/drugs/DB08690ExperimentalCategories: Compounds used in a research, industrial, or household settingDanoprevir
go.drugbank.com/drugs/DB11779InvestigationalDanoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
Icotinib
go.drugbank.com/drugs/DB11737InvestigationalIcotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc … . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).